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Background: A remarkable increase in the number of thyroid cancer cases has been reported in recent years;
however, the markers to predict high-risk groups have not been fully established.
Methods: We conducted a case–control study (257 cases and 257 controls) that was nested in the Cancer Screenee
Cohort Study between August 2002 and December 2010; the mean follow-up time for this study was 3.1 ± 2.2 years.
The levels of total triiodothyronine (TT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin (Tg),
anti-thyroperoxidase antibody (TPOAb), and anti-thyroglobulin antibody (TgAb) were measured using samples
with pre-diagnostic status. Logistic regression models were used to examine the association between thyroid
function/autoimmunity and thyroid cancer risk.
Results: When the markers were categorized by the tertile distributions of the control group, the highest tertile
of FT4 (OR = 1.73, 95% CI = 1.11 − 2.69) and the middle tertile of TSH (OR = 1.77, 95% CI = 1.14 − 2.74) were
associated with an increased risk of thyroid cancer by multivariate analyses. In addition, an elevated risk for
thyroid cancer was found in subjects with TPOAb levels above 30 IU/mL (OR = 8.47, 95% CI = 5.39 − 13.33 for
30–60 IU/mL and OR = 4.48, 95% CI = 2.59 − 7.76 for ≥60 IU/mL). Stratified analyses indicated that some of these
associations differed by sex, BMI, smoking status, and the duration of follow-up.
Conclusions: This study demonstrated that the levels of biomarkers of thyroid function/autoimmunity, particularly the
presence of TPOAb, might be used as diagnostic markers for predicting thyroid cancer risk. Our findings suggest that
careful monitoring of thyroid biomarkers may be helpful for identifying Korean populations at high-risk for thyroid
cancer.
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Thyroid cancer is the most frequent cancer among
endocrine tumors, and its incidence has been greatly
increasing in many countries [1]. In particular, the inci-
dence of thyroid cancer in Korea has increased rapidly
and has become one of the highest in the world [2].
Although the increased incidence rate of thyroid cancer is
partly attributed to the increased detection of subclinical* Correspondence: jskim@ncc.re.kr
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[3], studies have reported a true increase in thyroid cancer
incidence due to changes in lifestyle or environmental
factors (e.g., iodine intake, exposure to radiation) [4,5].
Recently, an effort has been made to predict the risk
of thyroid cancer using the markers of thyroid function/
autoimmunity [6-9]. Although the findings were inconsist-
ent, several studies found biomarkers that predicted thy-
roid cancer. Some studies have reported that higher levels
of thyroid-stimulating hormone (TSH) are associated with
an increased risk of thyroid malignancy [6,7], possibly
because of its role in affecting thyroid cell differentiation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies have suggested that thyroid autoantibodies could
be used as predictors of thyroid cancer risk based on the
association between thyroid autoimmune disease and thy-
roid cancer [9]. However, most studies have investigated
these associations retrospectively, which has the potential
for selection and referral biases.
In this study, we aimed to investigate whether blood
markers representing thyroid function and autoimmunity
could predict thyroid malignancy. We designed a nested
case–control study, which was affected little by bias, to
validate blood markers for thyroid malignancy.
Methods
Study population
We conducted a nested case–control study on partici-
pants in the ongoing Cancer Screenee Cohort Study
(CSCS) between August 2002 and December 2010,
which had a mean time of follow-up of 3.1 ± 2.2 years.
The CSCS is a prospective cohort study consisting of
participants of the Cancer Screening Program at the
National Cancer Center in South Korea. Participants
were aged 30 years or older, underwent health-screening
examinations, and were screened for selected cancers.
All of the participants were asked to complete a self-
administered questionnaire at the baseline evaluation.
The data collected in the baseline evaluation included
socio-demographic characteristics, personal and family
medical history, lifestyle factors, and reproductive fac-
tors. A total of 22,085 subjects provided written in-
formed consent and provided a blood sample for study
participation.
Ascertainment of cases and selection of controls
Potential cases diagnosed with thyroid cancer (ICD10
code C73) were ascertained by linkage to the Korea
Central Cancer Registry (KCCR) database, which was
used to identify the incidence of cancer in Korea.
Among 258 thyroid cancer patients, 257 patients were
selected after excluding those who were dead. Among
the potential controls (n = 21,827) who were not diag-
nosed with thyroid cancer, 3,740 participants were ex-
cluded because of the following reasons: death, missing
questionnaire data, history of other cancers, any thy-
roid disease, thyroid surgery, or thyroid-related medi-
cine. For each case, one control among the remaining
18,807 participants who was matched by entry age (same
age) and sex was selected. In total, 257 incident cases
and 257 controls were used for the final biomarker ana-
lysis (Figure 1). The participants were followed up from
the date of blood collection until December 31, 2010.
The study procedure was approved by the institutional
review board of the National Cancer Center (NCCNCS
13–698).Laboratory procedures
Blood samples were collected at the baseline evaluation
and stored at −80°C until analysis. The serum concentra-
tions of the following six biomarkers were measured for
both cases and controls: total triiodothyronine (TT3),
thyroid-stimulating hormone (TSH), free thyroxine (FT4),
thyroglobulin (Tg), anti-thyroglobulin antibody (TgAb), and
anti-thyroperoxidase antibody (TPOAb). We selected these
biomarkers of thyroid function/autoimmunity based on
their associations with thyroid cancer that had been
reported in previous studies [6-9,11].
The serum concentrations of TT3, TSH, Tg, FT4, TgAb,
and TPOAb were measured using an electrochemilumines-
cence immunoassay (ELCLIA; Molecular Analytics E170,
Roche kit, Roche, Mannheim, Germany), which had
reference (normal) ranges of 0.82 − 2.0 ng/mL for TT3,
0.27 − 4.20 μIU/mL for TSH, 0.93 − 1.70 ng/dL for
FT4, and 1.4 − 78.0 ng/mL for Tg. TgAb was defined as
negative if ≤115.0 IU/mL, and TPOAb was defined as
negative if ≤34.0 IU/mL. The detection limits were
20 IU/mL for TgAb and 30 IU/mL for TPOAb.
Statistical methods
The general characteristics of the study participants and
the risk factors for thyroid cancer were compared using
t-tests for continuous variables and chi-square tests for
categorical variables. To evaluate the association between
serum biomarkers and thyroid cancer risk, serum levels of
TT3, FT4, TSH, and Tg were categorized into three
groups based on those of the control group. The antibody
titers for TgAb and TPOAb were also categorized into ter-
tiles: the lowest tertile (under detection limit; 20 IU/mL
for TgAb and 30 IU/mL for TPOAb), the middle tertile
(over detection limit − < 60 IU/mL), and the highest tertile
(>60 IU/mL). Then, we performed unconditional and
conditional logistic regressions and calculated odds ra-
tios (ORs) and 95% confidence intervals (CIs) using
univariate and multivariate analyses. The lowest levels
of each biomarker were used as references. The multivari-
ate unconditional logistic regression models were adjusted
for age, sex, body mass index (BMI) (<23, 23 − < 25,
and ≥25 kg/m2), and cigarette smoking (nonsmoker,
former smoker, and current smoker). To analyze the
association between Tg levels and cancer risk, we excluded
subjects who were positive for TgAb because the presence
of TgAb hampers the usefulness of serum Tg as a
tumor marker [12]. To explore potential modifying
factors, analyses stratified according to sex, BMI (<23
and ≥23 kg/m2), and smoking status (nonsmoker and
former/current smoker) were conducted; these factors
showed different distributions between cases and controls
in this study and have been reported to affect thyroid
cancer risk [13,14]. We also conducted an analysis
stratified by the duration of follow-up. To examine the
11,834 Controls were excluded
•  Death (n=149)
• Missing questionnaire (n=1,334)
•  History of Cancer (n=1,264)
•  Thyroid disease (n=977)
•  Thyroid surgery (n=37)
•  Thyroid-related medicine (n=28)
1 Cases were excluded
•  Death (n=1)
Followed-up
Until December 31st, 2010










Participants of Cancer Screenee Cohort at NCC
from August, 2002-December, 2010 (n=22,085)G
Figure 1 Flowchart of the sampling process of the nested case-control samples.
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risk and other biomarkers, we also conducted analyses
stratified by the presence of TPOAb. Because uncondi-
tional regression produced more stable results for the
different subanalyses [15], only the results from the
unconditional analyses are presented in the tables. We
verified that both the conditional and unconditional
approaches gave approximately the same results for
the entire dataset.
All statistical analyses were performed using SAS 9.1
software (SAS Institute Inc., Cary, NC). A two-sided
P-value of less than 0.05 was regarded as statistically
significant.
Results
This study included 257 cases and 257 controls, of
whom 70% were women and 30% were men. We exam-
ined the differences in the general characteristics of the
study subjects according to thyroid cancer status (Table 1).
The mean age for cases and controls was 49.4 ± 8.9 years.
The cases were more likely to have a higher BMI than the
controls (P = 0.019); however, no differences with respect
to other variables were observed between the cases and
controls.
Table 2 presents the association between the biomarkers
of thyroid function/autoimmunity and thyroid cancer risk.
When the markers were categorized by the tertile distri-
butions of the control group, the highest tertile of FT4(OR = 1.73, 95% CI = 1.11 − 2.69) showed an increased
risk of thyroid cancer, while the middle tertile of TSH
(OR = 1.77, 95% CI = 1.14 − 2.74) was associated with
thyroid cancer risk. In addition, TPOAb levels greater
than 30 IU/mL (OR = 8.47, 95% CI = 5.39 − 13.33 for
30 − < 60 IU/mL and OR = 4.48, 95% CI = 2.59 − 7.76
for ≥60 IU/mL) were strongly associated with risk of
thyroid cancer when compared with those whose
TPOAb levels were less than 30 IU/mL.
The associations of some markers with thyroid cancer
risk appeared to be different when the data were stratified
by sex, BMI, smoking status, or the duration of follow-up
(Table 3). The association between FT4 levels and thyroid
cancer risk was only significant among women or those
with a BMI <23 kg/m2. The elevated risk for the middle
tertile of TSH was only significant among men, those with
a BMI ≥23 kg/m2, or former/current smokers. The levels
of TT3, FT4, and TSH were associated with thyroid can-
cer risk only when the duration of follow-up was shorter
than 3 years. However, in all of the analyses, the presence
of TPOAb strongly elevated the risk of thyroid cancer.
Additionally, we examined whether other known risk
factors showed different distributions according to the
presence of TPOAb, but no differences were observed
(Additional file 1: Table S1).
Finally, we examined the role of TPOAb in the associ-
ation between the other biomarkers (TT3, FT4, TSH,
Tg, and TgAb) and thyroid cancer risk (Table 4). The
Table 1 General characteristics of the study subjects
Controls (n = 257) Cases (n = 257) P-value
Age (years), means 49.4 ± 8.9 49.4 ± 8.9 0.994
BMI (kg/m2)
<23 125(48.6) 95(37.0) 0.019
23 − <25 68(26.5) 75(29.2)
≥ 25 64(24.9) 87(33.9)
Family history of cancer (yes)a 93(41.0) 108(46.4) 0.245
Family history of thyroid cancer (yes)a 5(2.2) 6(2.6) 0.794
Educational level
Elementary school or less 21(8.8) 23(9.8) 0.774
Middle school 19(7.9) 16(6.8)
High school 95(39.6) 84(35.9)
College or more 105(43.8) 115(47.4)
Monthly household incomeb
<200 35(16.6) 24(11.8) 0.102
200 − <400 56(26.5) 72(35.3)
>400 120(56.9) 108(52.9)
Marital status




Nonsmoker 147(64.8) 158(69.3) 0.215
Former smoker 33(14.5) 37(16.3)
Current smoker 47(20.7) 33(14.5)
Alcohol consumption
Nondrinker 87(36.4) 100(41.5) 0.208
Former drinker 7(2.9) 12(5.0)
Current drinker 145(60.7) 129(53.5)
Age at menarche (years)c




Menopause (yes)c 83(47.7) 79(43.9) 0.472
Age at menopause (years)c
<46 16(21.1) 12(17.7) 0.185
46 − <49 14(18.4) 8(11.8)
49 − <52 14(18.4) 23(33.8)
≥52 32(42.1) 25(36.8)
Type of menopausec
Natural 57(71.3) 51(64.6) 0.366
Surgery, Other 23(28.8) 28(35.4)
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Table 1 General characteristics of the study subjects (Continued)
Postmenopausal hormone use (ever)c 28(36.8) 20(30.8) 0.448
Parity (yes)c 157(96.3) 159(98.2) 0.315
aFirst-degree relative.
bUnit is 10,000 Korean won.
cOnly in women.
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stronger among those with TPOAb levels <30 IU/mL
(OR = 2.12, 95% CI = 1.06 − 4.24).
Discussion
This study prospectively investigated the association be-
tween biomarkers of thyroid function/autoimmunity and
thyroid cancer risk and found that differences in the
levels of thyroid biomarkers, particularly TPOAb, could
predict the incidence of thyroid cancer.
Several studies have examined the association between
thyroid function and thyroid cancer risk [6-8,16,17]. ATable 2 The association between the biomarkers of thyroid fu
Controls (n = 257) Cases (n = 25
TT3 (ng/mL)
<1.2 88(34.2) 79(30.7)








1.36 − <2.5 86(33.9) 111(43.7)
≥2.5 84(33.1) 84(33.1)
Tg (ng/mL)a
0 − <3.9 77(33.8) 67(29.7)








30 − <60 38(14.8) 131(51.0)
≥60 27(10.5) 49(19.1)
Abbreviations: CI, Confidence interval; OR, Odds ratio; TT3, Total triiodothyronine; FT
Anti-thyroglobulin antibody; TPOAb, Anti-thyroperoxidase antibody.
aAnalyzed only for TgAb-negative subjects; bThe detection limits used were 20 IU/m
*P <0.05.large population-based cohort study from Taiwan [8] has
investigated the incidence of cancer in patients with
hyperthyroidism and found that patients with hyperthy-
roidism were at an increased risk for thyroid cancer.
This group also reported that the duration of hyperthy-
roidism was related to increased risk of thyroid cancer.
In the present study, the levels of thyroid hormones
were normal in most of the study participants. However,
relatively higher levels of FT4 showed a positive associ-
ation with thyroid cancer risk. Because the association
between thyroid hormones and thyroid cancer risk has
not been sufficiently studied, the underlying mechanismsnction/autoimmunity and thyroid cancer risk
7) Crude OR (95% CI) Adjusted OR (95% CI)c
1.0(ref) 1.0(ref)
1.17(0.78 − 1.75) 1.18(0.78 − 1.79)
1.18(0.75 − 1.86) 1.21(0.75 − 1.94)
1.0(ref) 1.0(ref)
1.10(0.71 − 1.72) 1.05(0.66 − 1.65)
1.64(1.07 − 2.57)* 1.73(1.11 − 2.69)*
1.0(ref) 1.0(ref)
1.81(1.18 − 2.79)* 1.77(1.14 − 2.74)*
1.40(0.90 − 2.19) 1.37(0.87 − 2.16)
1.0(ref) 1.0(ref)
0.98(0.61 − 1.56) 0.97(0.60 − 1.55)
1.40(0.90 − 2.17) 1.40(0.89 − 2.19)
1.0(ref) 1.0(ref)
1.54(0.81 − 2.93) 1.58(0.82 − 3.06)
1.08(0.62 − 1.88) 1.13(0.64 − 2.00)
1.0(ref) 1.0(ref)
8.60(5.49 − 13.45)* 8.47(5.39 − 13.33)*
4.53(2.64 − 7.76)* 4.48(2.59 − 7.76)*
4, Free thyroxine; TSH, Thyroid-stimulating hormone; Tg, Thyroglobulin; TgAb,
L for TgAb and 30 IU/mL for TPOAb; cAdjusted for age, sex, BMI, and smoking.
Table 3 The association between thyroid function/autoimmunity biomarkers and thyroid cancer risk, stratified by sex, BMI, smoking status, and the duration
of follow-upa
Sex BMI (kg/m2) Smoking Follow-up duration
Men Women <23 ≥23 Non-smoker Former/Current smoker < 3 years ≥3 years
Controls/Cases 77/77 180/180 125/95 132/162 147/158 80/70 97/171 160/86
TT3 (ng/mL)
<1.2 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
1.2 − <1.4 1.66(0.68 − 4.04) 1.08(0.67 − 1.75) 1.16(0.63 − 2.15) 1.18(0.67 − 2.08) 0.92(0.55 − 1.54) 2.07(0.85 − 5.02) 1.81(1.03 − 3.20)* 0.93(0.47 − 1.83)
≥1.4 1.56(0.61 − 4.00) 1.22(0.69 − 2.14) 0.93(0.43 − 2.00) 1.50(0.81 − 2.78) 0.80(0.43 − 1.51) 1.97(0.80 − 4.89) 2.51(1.21 − 5.22)* 1.10(0.53 − 2.25)
FT4 (ng/dL)
<1.25 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
1.25 − <1.39 0.65(0.23 − 1.80) 1.19(0.71 − 2.00) 1.37(0.62 − 2.89) 0.91(0.51 − 1.64) 0.82(0.46 − 1.46) 1.05(0.42 − 2.66) 1.58(0.84 − 2.97) 0.73(0.36 − 1.46)
≥1.39 1.44(0.53 − 3.88) 1.76(1.06 − 2.92)* 2.52(1.28 − 4.96)* 1.43(0.78 − 2.60) 1.46(0.83 − 2.56) 1.85(0.77 − 4.41) 3.01(1.57 − 5.77)* 1.10(0.57 − 2.10)
TSH (μIU/mL)
<1.36 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
1.36 − <2.5 2.31(1.06 − 5.02)* 1.58(0.92 − 2.72) 1.16(0.59 − 2.29) 2.31(1.30 − 4.13)* 1.71(0.95 − 3.09) 2.44(1.14 − 5.24)* 2.07(1.11 − 3.88)* 1.57(0.80 − 3.06)
≥2.5 1.97(0.76 − 5.08) 1.16(0.68 − 1.97) 0.96(0.49 − 1.89) 1.82(0.98 − 3.37) 1.23(0.68 − 2.22) 1.33(0.53 − 3.38) 1.36(0.72 − 2.59) 1.41(0.70 − 2.83)
Tg (ng/mL)b
0 − <3.9 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
3.9 − <7 1.09(0.46 − 2.57) 0.93(0.52 − 1.66) 1.09(0.52 − 2.30) 0.95(0.52 − 1.77) 0.77(0.41 − 1.43) 1.16(0.48 − 2.79) 1.75(0.87 − 3.52) 0.65(0.32 − 1.33)
≥7 2.98(1.23 − 7.17)* 1.08(0.63 − 1.83) 1.09(0.55 − 2.14) 1.89(1.02 − 3.49)* 0.98(0.55 − 1.75) 2.52(1.05 − 6.03)* 1.80(0.96 − 3.36) 1.06(0.54 − 2.10)
TgAb (IU/mL)c
<20 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
20 − <60 1.77(0.31 − 10.20) 1.56(0.77 − 3.19) 1.92(0.77 − 4.79) 1.27(0.50 − 3.26) 1.54(0.71 − 3.33) 1.33(0.28 − 6.26) 1.25(0.55 − 2.83) 1.17(0.35 − 3.89)
≥60 0.25(0.03 − 2.22) 1.31(0.71 − 2.41) 1.16(0.49 − 2.77) 1.11(0.52 − 2.37) 1.14(0.53 − 2.47) 1.07(0.30 − 3.79) 1.67(0.71 − 3.92) 0.77(0.32 − 1.87)
TPOAb (IU/mL)c
<30 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref) 1.0(ref)
30 − <60 5.59(2.57 − 12.16)* 10.67(6.03 − 18.88)* 8.77(4.30 − 17.86)* 8.40(4.62 − 15.24)* 10.96(5.85 − 20.53)* 4.97(2.31 − 10.69)* 6.10(3.10 − 11.67)* 14.75(2.36 − 29.56)*
≥60 3.89(1.05 − 14.41)* 4.60(2.50 − 8.46)* 4.43(1.95 − 10.04)* 4.41(2.10 − 9.26)* 3.52(1.78 − 6.96)* 6.35(1.80 − 22.41)* 4.54(2.10 − 9.84)* 4.32(1.77 − 10.52)*
Abbreviations: BMI, Body mass index; CI, Confidence interval; OR, Odds ratio; TT3, Total triiodothyronine; FT4, Free thyroxine; TSH, Thyroid-stimulating hormone; Tg, thyroglobulin; TgAb, Anti-thyroglobulin antibody;
TPOAb, Anti-thyroperoxidase antibody.
aData were analyzed using multivariate logistic regression models which were adjusted for age, sex, BMI, and smoking; bAnalyzed only for TgAb-negative subjects; cThe detection limits used were 20 IU/mL for TgAb























Controls/cases Adjusted OR (95% CI)c Controls/cases Adjusted OR (95% CI)c
TT3 (ng/mL)
<1.2 67/29 1.0(ref) 21/50 1.0(ref)
1.2 − <1.4 74/32 1.03(0.55 − 1.91) 30/77 1.05(0.53 − 2.07)
≥1.4 51/16 0.71(0.34 − 1.49) 14/53 1.71(0.76 − 3.85)
FT4 (ng/dL)
<1.25 66/18 1.0(ref) 19/50 1.0(ref)
1.25 − <1.39 62/21 1.14(0.55 − 2.40) 23/54 0.87(0.42 − 1.80)
≥1.39 64/38 2.12(1.06 − 4.24)* 23/76 1.37(0.66 − 2.83)
TSH (μIU/mL)
<1.36 66/16 1.0(ref) 18/43 1.0(ref)
1.36 − <2.5 63/32 2.00(1.00 − 4.01)* 23/79 1.48(0.73 − 3.00)
≥2.5 63/28 1.82(0.89 − 3.72) 21/56 1.14(0.54 − 2.40)
Tg (ng/mL)a
0 − <3.9 58/22 1.0(ref) 19/45 1.0(ref)
3.9 − <7 59/18 0.70(0.34 − 1.44) 15/46 1.28(0.57 − 2.86)
≥7 63/32 1.21(0.63 − 2.32) 14/63 1.95(0.87 − 4.38)
TgAb (U/mL)b
<20 170/69 1.0(ref) 42/134 1.0(ref)
≥20 22/8 0.95(0.40 − 2.26) 23/46 0.59(0.31 − 1.14)
Abbreviations: CI, Confidence interval; OR, Odds ratio; TT3, Total triiodothyronine; FT4, Free thyroxine; TSH, Thyroid-stimulating hormone; Tg, Thyroglobulin; TgAb,
Anti-thyroglobulin antibody; TPOAb, Anti-thyroperoxidase antibody.
aAnalyzed only for TgAb-negative subjects; bThe detection limits used were 20 IU/mL for TgAb, and we combined these groups into two groups because of the
small sample sizes; cAdjusted for age, sex, BMI, and smoking.
*P <0.05.
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lating TSH receptor-stimulating antibodies (TSHR-Abs)
were present in all patients with Graves’ disease [18],
implying an association between TSHR-Abs and elevated
levels of thyroid hormones. TSHR-Abs are known to
stimulate the same intracellular signal pathways as TSH,
which has mitogenic and antiapoptotic effects on thyroid
follicular cells and thus may play a role in thyroid cancer
initiation [19].
The positive association between TSH levels and thy-
roid cancer risk has been reported in some studies
[6,7,16,17], implying that high TSH levels may play a
key role in the initiation of thyroid carcinogenesis. TSH
has a proliferative effect on thyroid cell growth that is
most likely mediated by TSH receptors on tumor cells
[17]. However, some studies did not find an association
between TSH levels and thyroid cancer risk [20]. Our
study demonstrated that the highest tertile of TSH levels
did not show any association with thyroid cancer, but the
medium tertile of TSH levels seemed to slightly increase
thyroid cancer risk.Tg is produced by normal thyroid tissue and neoplastic
follicular cells; therefore, serum Tg measurements can
be used as specific and sensitive tumor markers of differ-
entiated thyroid cancer in clinical practice [21]. The level
of serum Tg is known to aid in the detection of residual,
recurrent, or metastatic disease rather than in determin-
ing the incidence of thyroid cancer [22], but the role of
Tg in the initiation of thyroid cancer remains unclear.
However, this study has found that Tg is positively asso-
ciated with thyroid cancer risk only among lean people,
men, or smokers.
A high prevalence of thyroid cancer in those with
autoimmune thyroid diseases [23-25] and systemic auto-
immune diseases [26] may imply the possible association
between thyroid autoimmunity and cancer risk. Kim et al.
[24] found an elevated risk of papillary thyroid cancer in
Korean patients with Hashimoto’s thyroiditis with elevated
levels of TPOAb. Antonelli et al. [26] reported the higher
prevalence of papillary thyroid cancer in systemic lupus
erythematosus patients, particularly in patients with thy-
roid autoimmunity. The results of these studies suggest
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elevated levels of TPOAb. TPO is a membrane protein
that catalyzes thyroid hormone synthesis; thus, the pres-
ence of TPOAb in the blood may reflect an alteration in
the immune system and lymphocytic infiltration in the
thyroid [27]. TPOAb may destroy thyroid tissue as well as
cytokines produced by infiltrating inflammatory cells,
which may contribute to inflammation-induced carcino-
genesis [25,28,29]. Furthermore, the presence of TPOAb
could be associated with thyroid function. In a study using
the NHANES III survey from the United States, Hollowell
et al. reported an association between TPOAb and overt
thyroid dysfunction [30]. We also observed that the pres-
ence of TPOAb may affect the association between FT4
levels and the risk of thyroid cancer.
Several factors may modify the association between
thyroid abnormalities/thyroid autoimmunity and thyroid
cancer risk. First, the effect of FT4 and TSH on thyroid
cancer risk was affected by obesity status in the present
study. In addition, previous studies have reported a
positive association between obesity and thyroid cancer
[4,14]. It has also been proposed that obesity may affect
the secretion of certain hormones such as insulin and
sex steroids, which may act on the thyroid to stimulate
cell proliferation and suppress apoptosis [31]. Second,
this study also found that the levels of TSH and Tg were
associated with thyroid cancer risk only among smokers.
Smoking is known to have a negative association with
the risk of thyroid cancer [13,32], possibly by exerting
anti-estrogenic effects or by affecting the immune system
through nicotinic anti-inflammatory pathways [33-35].
Additionally, smoking is known to decrease the levels of
TSH and the positivity of thyroid autoantibodies [36],
which were reported to be positively associated with
thyroid cancer risk. Third, the association of these bio-
markers with thyroid cancer was different in men and
women. The higher levels of TPOAb in women and the
higher prevalence of smokers in men may partly explain
the observed differences in the incidence of thyroid can-
cer based on sex [32]. A negative association between
TPOAb and smoking was also reported [37].
The present study has strengths in its study design in
terms of ascertaining thyroid cancer patients within a
prospective cohort. This study design allowed for deter-
mining the potential role of pre-diagnostic serum levels
of biomarkers on thyroid cancer risk. In addition, the
controls were derived from the same cohort as the cases;
thus, the potential selection bias that can occur with a
conventional case–control study was minimized. However,
the findings from the present study should be interpreted
with caution because of several limitations. First, the
duration of follow-up in this study was relatively short.
However, the association between thyroid cancer and
the levels of TPOAb was not modified by duration offollow-up in this study. Second, we lacked detailed in-
formation on the specifics of the thyroid cancer, e.g.,
tumor stage and histological type, because case ascertain-
ment was performed by data linkage with the cancer regis-
try; therefore, we could not include these variables in our
analyses. Third, the sample size was relatively small, espe-
cially for a stratified analysis. Finally, the study population
consisted of participants in a cancer-screening program;
thus, these individuals may pay more attention to their
health status and may not be representative of the general
Korean population.
Conclusions
We found that the levels of biomarkers of thyroid function
and autoimmunity could provide additional information
for predicting thyroid malignancy. Particularly, the pres-
ence of TPOAb seems to be a strong predictor of thyroid
cancer. Interestingly, most participants who showed posi-
tive associations between these biomarkers and thyroid
cancer risk were in the normal ranges of these markers
and may not have had any symptoms of thyroid disease.
Therefore, we cautiously suggest that careful monitoring
of these biomarkers, even within the normal range, may
be helpful for identifying those at high risk for thyroid
cancer and for enhancing the likelihood of early detection
in Koreans.
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